PubRank

Jonathan M Schapiro

Author PubWeight™ 76.97‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009 8.37
2 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008 5.20
3 HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007 3.94
4 Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008 3.66
5 Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009 3.52
6 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005 3.17
7 Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006 3.06
8 Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 2008 2.91
9 Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010 2.91
10 HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008 2.88
11 HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005 2.86
12 Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007 2.79
13 Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006 2.33
14 Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005 2.04
15 Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004 2.00
16 Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004 1.84
17 Drug resistance mutations in HIV-1. Top HIV Med 2003 1.72
18 Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004 1.62
19 Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004 1.54
20 HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 2006 1.40
21 HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003 1.38
22 Drug resistance mutations in HIV-1. Top HIV Med 2004 1.37
23 Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother 2002 1.20
24 Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003 1.18
25 Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010 1.13
26 Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008 1.08
27 Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006 1.08
28 Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 2013 1.06
29 Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. J Infect Dis 2013 1.03
30 The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther 2004 0.98
31 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 2009 0.93
32 Drug resistance and antiretroviral drug development. J Antimicrob Chemother 2005 0.90
33 Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy. Pediatr Infect Dis J 2006 0.88
34 Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. AIDS Res Hum Retroviruses 2010 0.87
35 Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007 0.82
36 In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007 0.82
37 Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach. AIDS 2014 0.78
38 Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. J Antimicrob Chemother 2012 0.76
39 A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. J Antimicrob Chemother 2008 0.75